A detailed history of Royal Bank Of Canada transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 32,091 shares of ALLO stock, worth $72,846. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,091
Previous 29,014 10.61%
Holding current value
$72,846
Previous $67,000 32.84%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.08 - $3.5 $6,400 - $10,769
3,077 Added 10.61%
32,091 $89,000
Q2 2024

Aug 14, 2024

SELL
$2.23 - $4.38 $35,026 - $68,796
-15,707 Reduced 35.12%
29,014 $67,000
Q1 2024

Nov 05, 2024

BUY
$2.92 - $5.63 $45,864 - $88,430
15,707 Added 54.14%
44,721 $199,000
Q1 2024

May 15, 2024

SELL
$2.92 - $5.63 $52,816 - $101,835
-18,088 Reduced 28.8%
44,721 $199,000
Q4 2023

Feb 14, 2024

BUY
$2.28 - $3.5 $14,505 - $22,267
6,362 Added 11.27%
62,809 $201,000
Q3 2023

Nov 14, 2023

BUY
$3.17 - $5.96 $23,689 - $44,539
7,473 Added 15.26%
56,447 $178,000
Q2 2023

Aug 14, 2023

BUY
$4.53 - $6.74 $18,591 - $27,660
4,104 Added 9.15%
48,974 $243,000
Q1 2023

May 15, 2023

BUY
$4.92 - $8.21 $14,573 - $24,318
2,962 Added 7.07%
44,870 $221,000
Q4 2022

Feb 14, 2023

SELL
$5.62 - $11.11 $7,845 - $15,509
-1,396 Reduced 3.22%
41,908 $263,000
Q3 2022

Nov 14, 2022

SELL
$10.32 - $17.28 $1,919 - $3,214
-186 Reduced 0.43%
43,304 $468,000
Q2 2022

Aug 15, 2022

SELL
$6.78 - $12.28 $23,248 - $42,108
-3,429 Reduced 7.31%
43,490 $495,000
Q1 2022

May 16, 2022

SELL
$7.65 - $15.29 $138,204 - $276,229
-18,066 Reduced 27.8%
46,919 $427,000
Q4 2021

Feb 14, 2022

SELL
$13.13 - $24.52 $381,452 - $712,355
-29,052 Reduced 30.89%
64,985 $970,000
Q3 2021

Nov 15, 2021

BUY
$21.01 - $27.64 $20,400 - $26,838
971 Added 1.04%
94,037 $2.42 Million
Q2 2021

Aug 16, 2021

BUY
$23.49 - $35.8 $2.19 Million - $3.33 Million
93,066 New
93,066 $2.43 Million

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $326M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.